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In 2002, the joint International Programme on Chemical Safety 
(IPCS) of the World Health Organization (WHO), the United 
Nations Environment Programme (UNEP), and the International 
Labour Organisation (ILO) published a report titled Global Assessment 
of the State-of-the-Science of Endocrine Disruptors (http://www.who.int/
ipcs/publications/new_issues/endocrine_disruptors/en/). Since 2002, 
intense scientific work has improved our understanding of the impacts 
of endocrine-disrupting chemicals (EDCs) on human and wildlife 
health, such that in 2012, the UNEP and WHO, in collaboration with 
international experts, have produced an updated document on EDCs, 
State of the Science of Endocrine Disrupting Chemicals - 2012 (http://
www.who.int/ceh/publications/endocrine/en/index.html) that includes 
scientific information on human and wildlife impacts and lists key 
concerns for decision makers and others concerned about the future of 
human and wildlife health. 
The basis for these key concerns is described in the State of the 
Science of Endocrine Disrupting Chemicals - 2012 (http://www.who.
int/ceh/publications/endocrine/en/index.html) and includes extensive 
references to the science behind the concerns. A shorter summary, 
primarily for decision makers, elabo rates on the key concerns listed 
below and and also on suggested considerations related to EDCs (State 
of the Science of Endocrine Disrupting Chemicals - 2012: Summary for 
Decision-Makers; http://www.who.int/ceh/publications/endocrine/en/
index.html). 
The key concerns noted in the State of the Science of Endocrine 
Disrupting Chemicals - 2012 (http://www.who.int/ceh/publications/
endocrine/en/index.html) are as follows: 
Human and wildlife health depends on the ability to reproduce and •	
develop normally. This is not possible without a healthy endocrine 
system.
Three strands of evidence fuel concerns over endocrine disruptors:•	
The high incidence and the increasing trends of many endocrine- ǹ
related disorders in humans;
Observations of endocrine-related effects in wildlife populations; ǹ
The identification of chemicals with endocrine disrupting proper- ǹ
ties linked to disease outcomes in laboratory studies.
Many endocrine-related diseases and disorders are on the rise. •	
Large proportions (up to 40%) of young men in some countries  ǹ
have low semen quality, which reduces their ability to father 
children.
The incidence of genital malformations, such as non-descending  ǹ
testes (cryptorchidisms) and penile malformations (hypospadias), 
in baby boys has increased over time or levelled off at unfavour-
ably high rates.
The incidence of adverse pregnancy outcomes, such as preterm  ǹ
birth and low birth weight, has increased in many countries.
Neurobehavioural disorders associated with thyroid disruption  ǹ
affect a high proportion of children in some countries and have 
increased over past decades.
Global rates of endocrine-related cancers (breast, endometrial,  ǹ
ovarian, prostate, testicular and thyroid) have been increasing 
over the past 40–50 years.
There is a trend towards earlier onset of breast development in  ǹ
young girls in all countries where this has been studied. This is a 
risk factor for breast cancer.
The prevalence of obesity and type 2 diabetes has dramatically  ǹ
increased worldwide over the last 40 years. WHO estimates that 
1.5 billion adults worldwide are overweight or obese and that 
the number with type 2 diabetes increased from 153 million to 
347 million between 1980 and 2008.
Close to 800 chemicals are known or suspected to be capable of inter-•	
fering with hormone receptors, hormone synthesis or hormone con-
version. However, only a small fraction of these chemicals have been 
investigated in tests capable of identifying overt endocrine effects in 
intact organisms.
The vast majority of chemicals in current commercial use have  ǹ
not been tested at all.
This lack of data introduces significant uncertainties about the  ǹ
true extent of risks from chemicals that potentially could disrupt 
the endocrine system.
Human and wildlife populations all over the world are exposed to EDCs.•	
There is global transport of many known and potential EDCs  ǹ
through natural processes as well as through commerce, leading 
to worldwide exposure.
Unlike 10 years ago, we now know that humans and wildlife are  ǹ
exposed to far more EDCs than just those that are POPs [persis-
tent organic pollutants].
Levels of some newer POPs in humans and wildlife are still  ǹ
increasing, and there is also exposure to less persistent and less 
bioaccumulative, but ubiquitous, chemicals.
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New sources of human exposure to EDCs and potential EDCs, in  ǹ
addition to food and drinking-water, have been identified.
Children can have higher exposures to chemicals compared with  ǹ
adults—for example, through their hand-to-mouth activity and 
higher metabolic rate.
The speed with which the increases in disease incidence have •	
occurred in recent decades rules out genetic factors as the sole 
plausible explanation. Environmental and other non-genetic fac-
tors, including nutrition, age of mother, viral diseases and chemical 
exposures, are also at play, but are difficult to identify. Despite these 
difficulties, some associations have become apparent:
Non-descended testes in young boys are linked with exposure  ǹ
to diethylstilbestrol (DES) and polybrominated diphenyl ethers 
(PBDEs) and with occupational pesticide exposure during 
pregnancy. Recent evidence also shows links with the painkiller 
paracetamol. However, there is little to suggest that poly-
chlorinated biphenyls (PCBs) or dichlorodiphenyl dichloro ethylene 
(DDE) and dichloro diphenyltrichloro ethane (DDT) are associated 
with cryptorchidism.
High exposures to polychlorinated dioxins and certain PCBs (in  ǹ
women who lack some detoxifying enzymes) are risk factors 
in breast cancer. Although exposure to natural and synthetic 
estrogens is associated with breast cancer, similar evidence link-
ing estrogenic environmental chemicals with the disease is not 
available. 
Prostate cancer risks are related to occupational exposures to  ǹ
pesticides (of an unidentified nature), to some PCBs and to arse-
nic. Cadmium exposure has been linked with prostate cancer in 
some, but not all, epidemiological studies, although the associa-
tions are weak.
Developmental neurotoxicity with negative impacts on brain  ǹ
development is linked with PCBs. Attention deficit/hyperactivity 
disorder (ADHD) is overrepresented in populations with elevated 
exposure to organophosphate pesticides. Other chemicals have 
not been investigated.
An excess risk of thyroid cancer was observed among pesticide  ǹ
applicators and their wives, although the nature of the pesti-
cides involved was not defined. 
Significant knowledge gaps exist as to associations between expo-•	
sures to EDCs and other endocrine diseases, as follows:
There is very little epidemiological evidence to link EDC exposure  ǹ
with adverse pregnancy outcomes, early onset of breast develop-
ment, obesity or diabetes.
There is almost no information about associations between EDC  ǹ
exposure and endometrial or ovarian cancer.
High accidental exposures to PCBs during fetal development or  ǹ
to dioxins in childhood increase the risk of reduced semen qual-
ity in adulthood. With the exception of these studies, there are 
no data sets that include information about fetal EDC exposures 
and adult measures of semen quality.
No studies exist that explore the potential link between fetal  ǹ
exposure to EDCs and the risk of testicular cancer occurring 
20–40 years later.
Numerous laboratory studies support the idea that chemical expo-•	
sures contribute to endocrine disorders in humans and wildlife. The 
most sensitive window of exposure to EDCs is during critical periods 
of development, such as during fetal development and puberty.
Developmental exposures can cause changes that, while not evi- ǹ
dent as birth defects, can induce permanent changes that lead 
to increased incidence of diseases throughout life.
These insights from endocrine disruptor research in animals  ǹ
have an impact on current practice in toxicological testing and 
screening. Instead of solely studying effects of exposures in 
adulthood, the effects of exposures during sensitive windows in 
fetal develop ment, perinatal life, childhood and puberty require 
careful scrutiny.
Worldwide, there has been a failure to adequately address the •	
under lying environmental causes of trends in endocrine diseases and 
disorders.
Health-care systems do not have mechanisms in place to address  ǹ
the contribution of environmental risk factors to endocrine dis-
orders. The benefits that can be reaped by adopting primary pre-
ventive measures for dealing with these diseases and dis orders 
have remained largely unrealized.
Wildlife populations have been affected by endocrine disruption, with •	
negative impacts on growth and reproduction. These effects are wide-
spread and have been due primarily to POPs. Bans of these chemicals 
have reduced exposure and led to recovery of some populations.
It is therefore plausible that additional EDCs, which have been  ǹ
increasing in the environment and are of recent concern, are 
contributing to current population declines in wildlife species. 
Wildlife populations that are also challenged by other environ-
mental stressors are particularly vulnerable to EDC exposures.
Internationally agreed and validated test methods for the identifi-•	
cation of endocrine disruptors capture only a limited range of the 
known spectrum of endocrine disrupting effects. This increases the 
likelihood that harmful effects in humans and wildlife are being 
overlooked.
For many endocrine disrupting effects, agreed and validated test  ǹ
methods do not exist, although scientific tools and laboratory 
methods are available.
For a large range of human health effects, such as female repro- ǹ
ductive disorders and hormonal cancers, there are no viable 
laboratory models. This seriously hampers progress in under-
standing the full scale of risks.
Disease risk due to EDCs may be significantly underestimated.•	
A focus on linking one EDC to one disease severely under- ǹ
estimates the disease risk from mixtures of EDCs. We know that 
humans and wildlife are simultaneously exposed to many EDCs; 
thus, the measurement of the linkage between exposure to mix-
tures of EDCs and disease or dysfunction is more physiologically 
relevant. In addition, it is likely that exposure to a single EDC 
may cause disease syndromes or multiple diseases, an area that 
has not been adequately studied.
An important focus should be on reducing exposures by a variety of •	
mechanisms. Government actions to reduce exposures, while limited, 
have proven to be effective in specific cases (e.g. bans and restric-
tions on lead, chlorpyrifos, tributyltin, PCBs and some other POPs). 
This has contributed to decreases in the frequency of disorders in 
humans and wildlife.
Despite substantial advances in our understanding of EDCs, uncer-•	
tainties and knowledge gaps still exist that are too important to 
ignore. These knowledge gaps hamper progress towards better 
protection of the public and wildlife. An integrated, coordinated 
inter national effort is needed to define the role of EDCs in current 
declines in human and wildlife health and in wildlife populations.
With the present state of the science of EDCs, we are now poised 
to have an important impact on disease prevention. The increase 
in non communicable diseases in humans and wildlife over the past 
40 years indicates an important role of the environment in disease 
etiology. EDCs are an important component of the environmental 
influences on disease, along with nutrition and other factors. Thus, 
reducing exposures to EDCs could have an important impact on 
actual disease prevention. Prevention of disease is always better than 
intervening after the disease occurs, both in terms of cost and human 
suffering: The benefits of early action outweigh the costs. 
To take advantage of our current knowledge to improve human 
and wildlife health by preventing environmentally induced diseases, 
we propose the following ideas for considera tion (State of the Science of 
Endocrine Disrupting Chemicals - 2012: Summary for Decision-Makers; 
http://www.who.int/ceh/publications/endocrine/en/index.html):
Strengthening knowledge of EDCs: It is critical to move beyond 
the piecemeal, one chemical at a time, one disease at a time, one dose 
approach currently used by scientists studying animal models, humans 
or wildlife. Understanding the effects of the mixtures of chemicals 
to which humans and wildlife are exposed is increasingly important. 
Assessment of EDC action by scientists needs to take into account 
the charac teris tics of the endocrine system that are being disrupted, 
including tissue specificity and sensitive windows of exposure across 
the lifespan. While there are different perspectives on the importance 
of low-dose effects and non-monotonic dose–response curves for 
EDCs, this issue is important in determining whether current testing 
protocols are sufficient to identify EDCs. Interdisciplinary efforts that 
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combine knowledge from wildlife, experimental animal and human 
studies are needed to provide a more holistic approach for identify-
ing the chemicals that are responsible for the increased incidence of 
endocrine-related disease and dysfunction. The known EDCs may not 
be representative of the full range of relevant molecular structures 
and properties due to a far too narrow focus on halogenated chemi-
cals for many exposure assessments and testing for endocrine disrupt-
ing effects. Thus, research is needed to identify other possible EDCs. 
Endocrine disruption is no longer limited to estrogenic, androgenic 
and thyroid pathways. Chemicals also interfere with metabolism, fat 
storage, bone development and the immune system, and this sug-
gests that all endocrine systems can and will be affected by EDCs. 
Together, these new insights stress a critical need to acquire a better 
understanding of the endocrine system to determine how EDCs affect 
normal endocrine function, how windows of exposure may affect 
disease incidence (particularly for childhood respiratory diseases) and 
how these effects may be passed on to generations to come.
Furthermore, new approaches are needed to examine the effects 
of mixtures of endocrine disruptors on disease susceptibility and eti-
ology, as examination of one endocrine disruptor at a time is likely 
to under estimate the combined risk from simultaneous exposure to 
multiple endocrine disruptors. Assessment of human health effects 
due to EDCs needs to include the effects of exposure to chemical 
mixtures on a single disease as well as the effects of exposure to 
a single chemical on multiple diseases. Since human studies, while 
important, cannot show cause and effect, it is critical to develop 
cause and effect data in animals to support the studies on humans.
Improved testing for EDCs: Validated screening and testing 
systems have been developed by a number of governments, and it 
requires considerable time and effort to ensure that these systems 
function properly. These systems include both in vitro and in vivo end-
points and various species, including fish, amphibians and mammals. 
New approaches are also being explored whereby large batteries of 
high-throughput in vitro tests are being investigated for their ability 
to predict toxicity, the results of which may be used in hazard iden-
tification and potentially risk assessment. These new approaches are 
important as one considers the number of chemicals for which there 
is no information, and these high-throughput assays may provide 
important, albeit incomplete, information. An additional challenge 
to moving forward is that EDC research over the past decade has 
revealed the complex interactions of some chemicals with endocrine 
systems, which may escape detection in current validated test systems. 
Finally, it will be important to develop weight-of-evidence approaches 
that allow effective consideration of research from all  levels—from 
in vitro mechanistic data to human epidemiological data.
Reducing exposures and thereby vulnerability to disease: It 
is imperative that we know the nature of EDCs to which humans 
and wildlife are exposed, together with information about their 
concentrations in blood, placenta, amniotic fluid and other tissues, 
across lifespans, sexes, ethnicities (or species of wildlife) and regions. 
Many information gaps currently exist with regard to what is found 
in human and wildlife tissues, more so for developing countries and 
countries with economies in transition and for chemicals that are less 
bioaccumulative in the body. Long-term records to help us under-
stand changes in exposures exist only for POPs and only for a few 
countries.
In addition, there is a need to continue expanding the list of 
chemicals currently examined to include those contained in materials 
and goods as well as chemical by-products; it is impossible to assess 
exposure without knowing the chemicals to target. The comprehen-
sive measurement of all exposure events during a lifetime is needed, 
as opposed to biomonitoring at specific time points, and this requires 
longitudinal sampling, particularly during critical life stages, such as 
fetal development, early childhood and the reproductive years.
Wildlife and humans are exposed to a wide variety of EDCs that 
differ greatly in their physical and chemical properties. Further, these 
compounds are generally present at trace concentrations and in com-
plex matrices requiring highly selective and sensitive analytical meth-
ods for their measurement. The wide range of different compound 
classes requires a variety of analytical approaches and techniques, 
making it challenging to understand all of the different chemicals in 
the environment and in human and wildlife tissues. There is a grow-
ing need to develop new analytical techniques and approaches to 
prioritize the assessment of EDCs. There is global transport of EDCs 
through natural processes (ocean and air currents) as well as com-
merce, leading to worldwide exposures. New sources of exposure to 
EDCs, in addition to food, have been identified and include indoor 
environments and electronics recycling and dumpsites (of particular 
concern in developing countries and countries with economies in 
transition). The sources and routes of exposure to EDCs need to be 
further investigated.
Identifying endocrine active chemicals: Identifying chemicals 
with endocrine disrupting potential among all of the chemicals used 
and released worldwide is a major challenge, and it is likely that we 
are currently assessing only the “tip of the iceberg”. It is possible to 
trace high production volume chemicals, but that is not the case for 
the numerous additives and process chemicals. Adding greatly to the 
complexity, and to the number of chemicals in our environment, are 
the unknown or unintended by-products that are formed during 
chemical manufacturing, during combustion processes and via envi-
ronmental transformations. While the active ingredients in pharma-
ceuticals and pesticides have to be documented on the final product, 
this is not the case for chemicals in articles, materials and goods. 
Personal hygiene products and cosmetics require declarations of the 
ingredients, and the number of chemicals applied in this sphere of 
uses counts in the thousands. Many sources of EDCs are not known 
because of a lack of chemical constituent declarations in products, 
materials and goods. We need to know where the exposures are 
coming from.
Creating supportive environments for scientific advances, inno-
vation and disease prevention: Exposure to EDCs and their effects 
on human and wildlife health are a global problem that will require 
global solutions. More programs are needed that foster collabora-
tion and data sharing among scientists and between governmental 
agencies and countries. To protect human health from the combined 
effects of exposures to EDCs, poor nutrition and poor living condi-
tions, there is a need to develop programs and collaborations among 
developed and developing countries and those in economic transi-
tion. There is also a need to stimulate new adaptive approaches that 
break down institutional and traditional scientific barriers and stimu-
late inter disciplinary and multi disciplinary team science.
Methods for evaluating evidence: There is currently no widely 
agreed system for evaluating the strength of evidence of associations 
between exposures to chemicals (including EDCs) and adverse health 
outcomes. A transparent methodology is also missing. The need for 
developing better approaches for evaluating the strength of evi-
dence, together with improved methods of risk assessment, is widely 
recog nized. Methods for synthesizing the science into evidence-
based decisions have been developed and validated in clinical arenas. 
However, due to differences between environmental and clini cal 
health sciences, the evidence base and decision context of these 
methods are not applicable to exposures to environmental contami-
nants, including EDCs. To meet this challenge, it will be necessary to 
exploit new methodologi cal approaches. It is essential to evaluate 
associations between EDC exposures and health outcomes by further 
developing methods for which proof of concept is currently under 
development.
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